What is new for 2027
Our 2027 EQA catalogue adds a new Haemato-Oncology category, new EQA schemes and updates to existing programmes, so laboratories can find the right schemes for the tests they run.
Changes across the catalogue
- We have launched a new Haemato-Oncology category, with EQA schemes for molecular haemato-oncology.
- We have launched new EQA schemes for Newborn Screening, Neurofibromatosis, Epigenetic Signatures and MT-RNR1 testing.
- We have updated existing programmes and added new ways to take part.
Download the 2027 catalogue to plan your participation for the year ahead, or browse the schemes online.
Updates to specific schemes
Haemato-Oncology
Our new Haemato-Oncology category brings EQA schemes for molecular haemato-oncology. They evaluate both analytical performance and clinical interpretation. Find out more
Reproductive and Postnatal Genomics
Our new Newborn Screening EQA evaluates genomic newborn screening performance with clinically realistic samples for SMA, CFTR and PKU. It also includes an optional panel testing challenge.
Genomic and Inherited Disorders
New Neurofibromatosis and Epigenetic Signatures EQA schemes support quality and confidence in advanced genomic diagnostics, through independent assessment and educational feedback.
Pharmacogenetics
Our new pharmacogenomics EQA pilot assesses analytical performance and clinical interpretation of key MT-RNR1 variants associated with aminoglycoside-induced hearing loss.